Investments
40Portfolio Exits
8Partners & Customers
9Service Providers
1About PureTech
PureTech is a science-driven healthcare company, seeking to solve some of today's toughest health challenges through disruptive approaches. PureTech is problem-focused and solution-agnostic, looking beyond traditional disciplines and approaching healthcare problems from different perspectives. Focusing on areas of significant unmet medical need, PureTech evaluates and tests on average, 650 ideas per year and selects only the most scientifically and commercially promising concepts to advance.
Expert Collections containing PureTech
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find PureTech in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest PureTech News
Oct 8, 2022
PureTech’s next big step could be merger with cash-rich Nektar Companies’ management teams have ties via Chowrira, Robin By Paul Bonanos, Associate Editor October 7, 2022 9:37 PM UTC Years into its evolution beyond its affiliate model, PureTech is mulling a deal with Nektar that would deepen its commitment to developing a pipeline of its own, creating a well-funded company with five clinical assets spanning multiple immunology and oncology indications. PureTech Health plc (LSE:PRTC; NASDAQ:PRTC) disclosed late Thursday that it has discussed a deal in which Nektar Therapeutics (NASDAQ:NKTR) would acquire the biotech. The companies have exchanged non-binding proposals, and conversations remain ongoing; it’s not yet clear who would lead the combined organization... BCIQ Company Profiles
PureTech Investments
40 Investments
PureTech has made 40 investments. Their latest investment was in Vedanta Biosciences as part of their Series D on July 21, 2021.
PureTech Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/21/2021 | Series D | Vedanta Biosciences | $68M | No | 23 | |
7/7/2020 | Series B | Vor Biopharma | $110M | No | 12 | |
4/11/2019 | Convertible Note | Sonde Health | $6M | No | 1 | |
4/11/2019 | Series A | |||||
3/18/2019 | Convertible Note - II |
Date | 7/21/2021 | 7/7/2020 | 4/11/2019 | 4/11/2019 | 3/18/2019 |
|---|---|---|---|---|---|
Round | Series D | Series B | Convertible Note | Series A | Convertible Note - II |
Company | Vedanta Biosciences | Vor Biopharma | Sonde Health | ||
Amount | $68M | $110M | $6M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 23 | 12 | 1 |
PureTech Portfolio Exits
8 Portfolio Exits
PureTech has 8 portfolio exits. Their latest portfolio exit was Akili Interactive Labs on August 19, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
8/19/2022 | Reverse Merger | 4 | |||
Date | 8/19/2022 | ||||
|---|---|---|---|---|---|
Exit | Reverse Merger | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 |
PureTech Acquisitions
2 Acquisitions
PureTech acquired 2 companies. Their latest acquisition was Alivio Therapeutics on June 16, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/16/2021 | Acquired | 2 | ||||
1/1/1970 |
Date | 6/16/2021 | 1/1/1970 |
|---|---|---|
Investment Stage | ||
Companies | ||
Valuation | ||
Total Funding | ||
Note | Acquired | |
Sources | 2 |
PureTech Partners & Customers
9 Partners and customers
PureTech has 9 strategic partners and customers. PureTech recently partnered with China Medical System on June 6, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
6/18/2020 | Licensee | China | PureTech Founded Entity Gelesis Announces Partnership for Commercial Launch of Plenity® in China. PureTech , a clinical-stage biotherapeutics company dedicated to discovering , developing and commercialising highly differentiated medicines for devastating diseases , is pleased to note that its Founded Entity Gelesis today announced a partnership with China Medical System Holdings Ltd. for the commercialisation of Plenity in China . | 1 | |
12/17/2019 | Partner | ||||
5/27/2019 | Licensee | ||||
4/17/2019 | Partner | ||||
4/17/2019 | Partner |
Date | 6/18/2020 | 12/17/2019 | 5/27/2019 | 4/17/2019 | 4/17/2019 |
|---|---|---|---|---|---|
Type | Licensee | Partner | Licensee | Partner | Partner |
Business Partner | |||||
Country | China | ||||
News Snippet | PureTech Founded Entity Gelesis Announces Partnership for Commercial Launch of Plenity® in China. PureTech , a clinical-stage biotherapeutics company dedicated to discovering , developing and commercialising highly differentiated medicines for devastating diseases , is pleased to note that its Founded Entity Gelesis today announced a partnership with China Medical System Holdings Ltd. for the commercialisation of Plenity in China . | ||||
Sources | 1 |
PureTech Service Providers
1 Service Provider
PureTech has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Investment Bank | Bookrunner |
Service Provider | |
|---|---|
Associated Rounds | |
Provider Type | Investment Bank |
Service Type | Bookrunner |
Partnership data by VentureSource
PureTech Team
15 Team Members
PureTech has 15 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
David R. Elmaleh | Founder | Current | |
Name | David R. Elmaleh | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Founder | ||||
Status | Current |
Compare PureTech to Competitors
InDex Pharmaceuticals develops drugs to increase the quality of life of patients suffering from immunological diseases. It is based in Solna, Sweden.
Intact Therapeutics develops smart gels for local drug delivery for gastrointestinal diseases.
Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, global pharmaceutical company.
Loading...